COMP <GO>
CORT vs ABBV // FORWARD P/E MULTIPLE
Corcept Therapeutics Incorporated (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CORT 6
— ABBV 8
▲ FORWARD P/E MULTIPLE LEADER: CORT
LAST: $85.95 (-0.38%) • MKT CAP: $9.29B
forward-pe
78.3x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | CORT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | 29.00% | -24.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 33.3x | +61.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | 3.47% | -1.94 | ABBV | /fcf-yield <GO> |
| Operating Margin | 5.90% | 24.60% | -18.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 6.90% | +6.20 | CORT | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 8.60% | +4.20 | CORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 65.1 | -34.20 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.15 | -0.27 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 78.3x | 113.1x | -34.80 | CORT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.29B | $513.86B | -$504.57B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | ABBV REV | CORT GROSS % | ABBV GROSS % | CORT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $61.16B | 98.3% | 70.2% | $141.8M | $17.82B |
| FY 2024 | $675.0M | $56.33B | 98.4% | 70.0% | $196.1M | $17.83B |
| FY 2023 | $482.4M | $54.32B | — | — | $105.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
ABBV // BETA 1.15